Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

Tameka Bailey, Haitao Luan, Robert Clubb, Mayumi Naramura, Vimla Band, Srikumar Raja, Hamid Band

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The Human Epidermal Growth Factor Receptor 2 (Her2, ErbB2 or Neu) is overexpressed in about 20-25% of breast cancers and is causally linked to oncogenesis, providing opportunities for targeted therapy. Trastuzumab (Herceptin™, Genentech Inc, San Francisco, CA), a humanized monoclonal antibody against ErbB2, is a successful example of this concept and has vastly improved the response to treatment and overall survival in a majority of ErbB2+ breast cancer patients. However, lack of response in some patients as well as relapse during the course of therapy in others, continue to challenge researchers and clinicians alike towards a better understanding of the fundamental mechanisms of Trastuzumab action and resistance to treatment. The exact in vivo mechanism of action of Trastuzumab remains enigmatic, given its direct effects on the ErbB2 signaling pathway as well as indirect contributions from the immune system, by virtue of the ability of Trastuzumab to elicit Antibody-Dependent Cellular Cytotoxicity. Consequently, multiple mechanisms of resistance have been proposed. We present here a comprehensive review of our current understanding of the mechanisms, both of Trastuzumab action and clinical resistance to Trastuzumab-based therapies. We also review newer strategies (based on ErbB2 receptor biology) that are being explored to overcome resistance to Trastuzumab therapy.

Original languageEnglish (US)
Article number28
JournalJournal of Carcinogenesis
Volume10
DOIs
StatePublished - Dec 1 2011

Fingerprint

Breast Neoplasms
Therapeutics
Antibodies, Monoclonal, Humanized
San Francisco
Trastuzumab
Immune System
Carcinogenesis
Research Personnel
Recurrence
Survival
Antibodies

Keywords

  • ErbB2 (Her2/Neu)
  • mechanism
  • resistance
  • trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Health, Toxicology and Mutagenesis

Cite this

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. / Bailey, Tameka; Luan, Haitao; Clubb, Robert; Naramura, Mayumi; Band, Vimla; Raja, Srikumar; Band, Hamid.

In: Journal of Carcinogenesis, Vol. 10, 28, 01.12.2011.

Research output: Contribution to journalArticle

@article{92d23918fc1349b68084bccc59905210,
title = "Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance",
abstract = "The Human Epidermal Growth Factor Receptor 2 (Her2, ErbB2 or Neu) is overexpressed in about 20-25{\%} of breast cancers and is causally linked to oncogenesis, providing opportunities for targeted therapy. Trastuzumab (Herceptin™, Genentech Inc, San Francisco, CA), a humanized monoclonal antibody against ErbB2, is a successful example of this concept and has vastly improved the response to treatment and overall survival in a majority of ErbB2+ breast cancer patients. However, lack of response in some patients as well as relapse during the course of therapy in others, continue to challenge researchers and clinicians alike towards a better understanding of the fundamental mechanisms of Trastuzumab action and resistance to treatment. The exact in vivo mechanism of action of Trastuzumab remains enigmatic, given its direct effects on the ErbB2 signaling pathway as well as indirect contributions from the immune system, by virtue of the ability of Trastuzumab to elicit Antibody-Dependent Cellular Cytotoxicity. Consequently, multiple mechanisms of resistance have been proposed. We present here a comprehensive review of our current understanding of the mechanisms, both of Trastuzumab action and clinical resistance to Trastuzumab-based therapies. We also review newer strategies (based on ErbB2 receptor biology) that are being explored to overcome resistance to Trastuzumab therapy.",
keywords = "ErbB2 (Her2/Neu), mechanism, resistance, trastuzumab",
author = "Tameka Bailey and Haitao Luan and Robert Clubb and Mayumi Naramura and Vimla Band and Srikumar Raja and Hamid Band",
year = "2011",
month = "12",
day = "1",
doi = "10.4103/1477-3163.90442",
language = "English (US)",
volume = "10",
journal = "Journal of Carcinogenesis",
issn = "0974-6773",
publisher = "Medknow Publications and Media Pvt. Ltd",

}

TY - JOUR

T1 - Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance

AU - Bailey, Tameka

AU - Luan, Haitao

AU - Clubb, Robert

AU - Naramura, Mayumi

AU - Band, Vimla

AU - Raja, Srikumar

AU - Band, Hamid

PY - 2011/12/1

Y1 - 2011/12/1

N2 - The Human Epidermal Growth Factor Receptor 2 (Her2, ErbB2 or Neu) is overexpressed in about 20-25% of breast cancers and is causally linked to oncogenesis, providing opportunities for targeted therapy. Trastuzumab (Herceptin™, Genentech Inc, San Francisco, CA), a humanized monoclonal antibody against ErbB2, is a successful example of this concept and has vastly improved the response to treatment and overall survival in a majority of ErbB2+ breast cancer patients. However, lack of response in some patients as well as relapse during the course of therapy in others, continue to challenge researchers and clinicians alike towards a better understanding of the fundamental mechanisms of Trastuzumab action and resistance to treatment. The exact in vivo mechanism of action of Trastuzumab remains enigmatic, given its direct effects on the ErbB2 signaling pathway as well as indirect contributions from the immune system, by virtue of the ability of Trastuzumab to elicit Antibody-Dependent Cellular Cytotoxicity. Consequently, multiple mechanisms of resistance have been proposed. We present here a comprehensive review of our current understanding of the mechanisms, both of Trastuzumab action and clinical resistance to Trastuzumab-based therapies. We also review newer strategies (based on ErbB2 receptor biology) that are being explored to overcome resistance to Trastuzumab therapy.

AB - The Human Epidermal Growth Factor Receptor 2 (Her2, ErbB2 or Neu) is overexpressed in about 20-25% of breast cancers and is causally linked to oncogenesis, providing opportunities for targeted therapy. Trastuzumab (Herceptin™, Genentech Inc, San Francisco, CA), a humanized monoclonal antibody against ErbB2, is a successful example of this concept and has vastly improved the response to treatment and overall survival in a majority of ErbB2+ breast cancer patients. However, lack of response in some patients as well as relapse during the course of therapy in others, continue to challenge researchers and clinicians alike towards a better understanding of the fundamental mechanisms of Trastuzumab action and resistance to treatment. The exact in vivo mechanism of action of Trastuzumab remains enigmatic, given its direct effects on the ErbB2 signaling pathway as well as indirect contributions from the immune system, by virtue of the ability of Trastuzumab to elicit Antibody-Dependent Cellular Cytotoxicity. Consequently, multiple mechanisms of resistance have been proposed. We present here a comprehensive review of our current understanding of the mechanisms, both of Trastuzumab action and clinical resistance to Trastuzumab-based therapies. We also review newer strategies (based on ErbB2 receptor biology) that are being explored to overcome resistance to Trastuzumab therapy.

KW - ErbB2 (Her2/Neu)

KW - mechanism

KW - resistance

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84860135634&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860135634&partnerID=8YFLogxK

U2 - 10.4103/1477-3163.90442

DO - 10.4103/1477-3163.90442

M3 - Article

C2 - 22190870

AN - SCOPUS:84860135634

VL - 10

JO - Journal of Carcinogenesis

JF - Journal of Carcinogenesis

SN - 0974-6773

M1 - 28

ER -